Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis

Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis

Purpose of the study Head, neck (HN), and face involvement in atopic dermatitis (AD) poses a major psychological burden and can be challenging to effectively treat. New appearance of HN dermatitis has been reported with biologics used to treat AD. Lebrikizumab (LEBRI), a monoclonal targeting IL-13,...

Full description

Saved in:
Bibliographic Details
Main Authors: Jenny E. Murase, Kilian Eyerich, Raj Chovatiya, H. Chih-ho Hong, Christine Bangert, Lindsay Strowd, Mette Deleuran, Amber Reck Atwater, Maria Jose Rueda, Hany Elmaraghy, Maria Lucia Buziqui Piruzeli, Ignasi Pau-Charles, Fan Emily Yang, Jinglin Zhong, Delphine Staumont-Sallé
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Journal of Dermatological Treatment
Subjects:
Head and neck dermatitis
facial erythema
lebrikizumab
atopic dermatitis
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2025.2492188
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/09546634.2025.2492188

Similar Items